TY - JOUR AU - Patel, Avi AU - Cohen, Sarah AU - Moret, Ravan AU - Maresh, Grace AU - Gobe, Glenda C. AU - Li, Li PY - 2018 TI - Patient-derived xenograft models to optimize kidney cancer therapies JF - Translational Andrology and Urology; Vol 8, Supplement 2 (May 31, 2019): Translational Andrology and Urology (Kidney Disease) Y2 - 2018 KW - N2 - Renal cell carcinoma (RCC) is the most common solid neoplasm of the adult kidney and has a high potential for developing metastatic spread. Approximately 25–30% of RCC patients have metastatic disease at presentation, and 30–40% of patients develop metastases after the initial diagnosis. Advanced renal cancer is a deadly and difficult-to-treat cancer. The 5-year survival rate of patients with metastatic disease is less than 10%, partly because RCC metastases become resistant to current therapies. Pre-clinical models may help to identify the optimum therapeutic options for individual patients. Here we reviewed various mouse xenograft methods for RCC treatment screening especially patient-derived orthotopic xenograft models. Advantages and disadvantaged of some of the models are also discussed. UR - https://tau.amegroups.org/article/view/22650